In metastatic colorectal cancer (mCRC), liver-limited disease (LLD) is associated with a higher chance of metastectomy leading to long-term survival. However, limited data describes the prognostic and predictive relevance of initially unresectable LLD with regard to targeted first-line therapy. The present analysis investigated the relevance of initially unresectable LLD in mCRC patients treated with targeted therapy against either the epidermal growth factor receptor (EGFR) or vascular epithelial growth factor (VEGF). The analysis was performed based on FIRE-3, a randomized phase III trial comparing first-line chemotherapy with FOLFIRI plus either cetuximab (anti-EGFR) or bevacizumab (anti-VEGF) in RAS wild-type (WT) mCRC. Of 400 patients, 133 (33.3%) had LLD and 267 (66.8%) had non-LLD. Median overall survival (OS) was significantly longer in LLD compared to non-LLD patients (36.0 vs. 25.4 months; hazard ratio [HR] 5 0.66; 95% confidence interval [CI] : 0.51-0.87; p 5 0.002). In a multivariate analysis also including secondary hepatic resection as time-dependent variable, LLD status was independently prognostic for OS (HR 5 0.67; 95% CI: 0.50-0.91; p 5 0.01). As assessed by interaction tests, treatment benefit from FOLFIRI plus cetuximab compared to FOLFIRI plus bevacizumab was independent of LLD status with regard to objective response rate (ORR), early tumour shrinkage 20% (ETS), depth of response (DpR) and OS (all p > 0.05). In conclusion, LLD could be identified as a prognostic factor in RAS-WT mCRC, which was independent of hepatic resection in patients treated with targeted therapy. LLD had no predictive relevance since benefit from FOLFIRI plus cetuximab over bevacizumab was independent of LLD status.
Colorectal cancer is the third most commonly diagnosed cancer in males and the second in females, with an estimated 1.4 million cases and 693,900 deaths occurring in 2012 worldwide. 1 Almost half of the patients develop metastases during the course of disease, with the liver being the most common site of dissemination. 2, 3 The metastases are confined to the liver in 44-77%. 4, 5 Among patients with liver-limited disease (LLD), it has been reported that 10-30% have a potentially resectable disease that can be treated with curative intent at the time of detection. 6 The resection of LLD leads to 5-year survival rates of up to 40%. 7 Further, there is also evidence that chemotherapy with or without targeted therapy may induce superior outcome in initially unresectable LLD patients most probably due to conversion of unresectable to resectable disease. [8] [9] [10] [11] Indeed, several studies have indicated that the use of anti-epidermal growth factor receptor (EGFR)-directed agents was associated with improved resectability of colorectal liver metastases achieving conversion rates up to 60%. [12] [13] [14] Accordingly, also the recent ESMO consensus guideline recommends a chemotherapy doublet plus an anti-EGFR agent in RAS-WT metastatic colorectal cancer (mCRC) where tumour shrinkage is a primary goal of treatment. 15 However, no data exist to evaluate the predictive relevance of initially unresectable LLD in the comparative setting of anti-EGFR and anti-vascular endothelial growth factor (VEGF) therapy. Further, LLD has not been investigated as prognostic factor in patients with initially unresectable disease treated with targeted therapy. Hence, the present analysis investigates besides the prognostic relevance of LLD also its predictive relevance as a determinant of treatment efficacy induced by cetuximab (anti-EGFR) and bevacizumab (anti-VEGF) as applied in the FIRE-3 trial.
Patients and Methods

Study design
FIRE-3/AIO KRK0306 was a prospective, multicentre, randomized, open-label, phase III study (clinicaltrials.gov identifier NCT00433927). The study design has been described elsewhere. 16 Briefly, FIRE-3 compared FOLFIRI combined with either cetuximab or bevacizumab as first-line treatment of patients with unresectable mCRC and KRAS-WT tumours. Resectability was assessed locally, with the recommendation in the study protocol of involving a multidisciplinary team (MDT). Altogether, 114 centres contributed to the patient recruitment. In a retrospective analysis, patients with RAS-WT tumours (i.e. wild-type in KRAS and NRAS exons 2-4) were identified. 17 Details regarding the conduct of the trial, the full study population, treatment schedules, concordance with the Declaration of Helsinki and approval of ethics committees were reported previously. 16 
Patient population
In light of the adoption of RAS analyses as an improved biomarker of response to cetuximab therapy and its evaluation in FIRE-3, we decided to perform the present analyses in the RAS-WT population as previously described. 17, 18 In this 
Statistical analysis
The primary end point of FIRE-3 was objective response rate (ORR). Secondary end points were OS, progression-free survival (PFS), DpR, secondary hepatic resection with curative intent as well as safety and tolerability. The statistical design of FIRE-3 has been described elsewhere. 16 ETS and DpR were evaluated as previously described with cut-off for ETS at 20%. 17, 19 PFS and OS curves by LLD status and treatment arm were estimated using the Kaplan-Meier method; differences were assessed using a log-rank test. A Cox regression model was used to estimate HR. Interactions between treatment arms and LLD status were assessed through a likelihood ratio test. Interaction tests were considered negative with p > 0.05, indicating a lack of evidence that treatment outcome differed by LLD status. Fisher's exact test was applied to compare dichotomous variables between subgroups. Continuous variables were described as medians and compared by Mann-Whitney U test. OS analyses were conducted using a Cox regression model adjusting for treatment and LLD status in combination with possibly prognostic baseline factors. 20 Further, secondary hepatic resection with curative intent was evaluated as timedependent variable. Univariate and multivariate analyses were performed. Laboratory variables (alkaline phosphatase, LDH, CEA and Ca19.9) were log-transformed to enhance symmetric distribution before inclusion into the Cox models. Missing parameters were imputed according to a missing at random assumption using a multivariate approach by chained equations (MICE). Validity of the results was assessed by performing the same analyses on an alternative dataset with exclusion of variables with the largest missing information (LDH, Nstage Ca19.9 and CEA). To this end, the HRs between the models were compared (Supporting Information Fig. S1 ). The significant level was set to 0.05, only two-sided tests were considered. Statistical analyses were implemented in R version 3.2.2. The packages survival, Forest-plot and MICE were used to calculate survival analyses and the multiple imputations.
Results
Patient population
In the RAS-WT population of FIRE-3 (n 5 400), the median follow-up was 22.6 months (range 0.03-72.0 months). At the time of the present analysis, 265 of the 400 patients in this population had died and 351 had disease progression. Of the 400 patients with RAS-WT tumours, 133 (33.3%) had LLD and 267 (66.8%) non-LLD. Baseline parameters and clinical characteristics of patients with LLD and non-LLD were well balanced between both subgroups except that non-LLD patients were three times more often male, whereas this imbalance was less evident in the LLD group (1.4-fold) ( Table 1 ). Regarding prior treatment before randomization, LLD patients had received radiotherapy and adjuvant treatment less frequently when compared to non-LLD patients. Furthermore, LLD was diagnosed rather synchronously, whereas non-LLD was diagnosed more often metachronously. Finally, the primary tumour of non-LLD patients tended to be diagnosed at a higher T-stage at first diagnosis.
Outcome parameters according to LLD status
In patients with RAS-WT tumours, ORR was numerically, but not significantly, higher in LLD compared to non-LLD patient s (75.8% vs. 67.7%; p 5 0.14). Moreover, the rate of ETS (61.4% vs. 60.6%; p 5 0.90) and DpR (-34.0% vs. (Fig. 1) .
The prognostic relevance of LLD
A differential prognostic relevance of LLD within the treatment arms of FIRE-3 was evaluated ( Table 2 (Fig. 2) .
Hepatectomy in LLD patients
A total of 29 secondary hepatic resections with curative intent were performed among LLD patients resulting in a favourable median OS of 56.2 months (Supporting Information Fig. S2 ). LLD status was associated with a secondary Cancer Therapy and Prevention hepatic resection (21.8% in LLD vs. 6.7% in non-LLD patients; p < 0.0001). This finding was independent of treatment arm (likelihood ratio test: p 5 0.65).
The predictive relevance of LLD status
The treatment effects in patients with LLD and non-LLD were evaluated as shown ( 
Discussion
We investigated the prognostic and predictive relevance of LLD in the comparative setting of anti-EGFR and anti-VEGF directed antibodies in mCRC patients treated in the FIRE-3 study. An important finding of FIRE-3 was prolonged OS favouring FOLFIRI plus cetuximab compared to FOLFIRI plus bevacizumab in the absence of statistically significant differences in PFS and ORR (primary end point). 16, 17 The response-related outcome parameter ETS and DpR, obtained by independent radiological review, clearly related to the OS benefit conferred by FOLFIRI plus cetuximab in patients with RAS-WT tumours. With regard to response-related outcome parameters (ORR, ETS and DpR), no significant differences were observed between LLD and non-LLD patients in FIRE-3. In clear contrast, LLD status was associated with secondary hepatic resection leading to an excellent median OS of 56.2 months. This compares well to previous findings from unselected patients who had been treated with chemotherapy only. 9 In the FIRE-1 trial comparing FUFIRI to mIROX, median OS was 48 months in LLD patients who became resectable during treatment. Here, secondary hepatic resection was the critical determinant of prolonged survival in LLD patients as non-resected patients with LLD had comparable outcome to patients with non-LLD.
17
On this basis, we evaluated LLD status as prognostic factor in the FIRE-3 study. In contrast to findings of the FIRE-1 trial, LLD status was identified as a prognostic factor for OS independent of secondary hepatic resection. After adjusting for hepatic resection and potentially prognostic baseline parameters, 20 LLD compared to non-LLD status was associated with a significantly superior OS (HR 0.67, p 5 0.01).
As patients of the FIRE-1 trial had been treated with chemotherapy only, our results are the first to indicate that LLD is associated with favorable prognosis independent of hepatic resection in patients treated with anti-EGFR or anti-VEGF therapy as applied in FIRE-3. To account for the prognostic relevance of LLD, this parameter should be integrated into standard reporting of clinical trials evaluating systemic treatment of mCRC.
We next focused on the predictive relevance of LLD for treatment benefit from FOLFIRI plus either cetuximab versus bevacizumab in the FIRE-3 study. LLD and non-LLD patients both had a significant benefit from treatment with FOLFIRI plus cetuximab compared to FOLFIRI plus bevacizumab with regard to ETS and DpR. Further, treatment with cetuximab significantly favoured ORR in patients with non-LLD and numerically in patients with LLD. Finally, the OS benefit from FOLFIRI plus cetuximab observed in the RAS-WT population at comparable PFS could be recapitulated in the present subgroup analysis for both, LLD and non-LLD patients. 17 Here, the survival benefit for FOLFIRI plus cetuximab compared to bevacizumab was evident with comparable risk reduction and a negative interaction test.
Our findings nicely complement those of a previous subgroup analysis of the CRYSTAL study, where RAS-WT patients had been treated with either first-line FOLFIRI or FOLFIRI plus cetuximab. 11 For both, LLD and non-LLD patients, the addition of cetuximab to FOLFIRI increased ORR and R0 resection rate along with PFS and OS. The Figure 2 . Evaluation of independent prognostic factors on overall survival using a multivariate Cox regression analysis in the RAS wild-type population of the FIRE-3 trial. Missing values were imputed according to a missing at random assumption using a multivariate approach by chained equations. For continuous parameters, each increase by 1 led to an increased HR as displayed. Laboratory variables (alkaline phosphatase, LDH, CEA and Ca19.9) were log-transformed to enhance symmetric distribution before inclusion in the model. OS, overall survival; WBC, white blood cell count; LDH, lactate dehydrogenase; LLD, liver-limited disease; LuLD, lung-limited disease.
authors concluded that this finding might validate the hypothesis of improved ORR inducing improved resectability, which, in turn, results in improved long-term survival. Our current analyses extend the previous findings and indicate that combining cetuximab to FOLFIRI favours treatment response and survival irrespective of LLD status when compared to FOLFIRI alone and when compared to FOLFIRI plus bevacizumab. Hence, in the light of all available evidence and also based on the present analyses, it seems conceivable to initiate anti-EGFR-based treatment for patients with RAS-WT mCRC irrespectively of LLD status. 8, 11, 13, 15, 21 Worthy of note, the resection rates in patients with LLD (RAS-WT) differed considerably between FIRE-3 (21.8%) and CRYSTAL study (11.4%). 11, 16 Here, a head-to-head comparison of the two trials is hampered by the fact that resectability was not validated centrally by an independent review of hepatic imaging and response as well as independent surgical review, for example as in the CELIM trial. 13 Further, a coherent definition of unresectability is missing. 10 However, considering the recruitment periods of the two studies (CRYSTAL: 2004 (CRYSTAL: -2005 FIRE-3: 2007 FIRE-3: -2012 , it is assumable that the implementation of multidisciplinary team (MDT) working and the increasing cooperation between medical oncologists and surgeons might have contributed to the augmented resection rates and improved outcomes. 22 This underlines the importance of MDTs to define treatment strategies for individual patients as well as the need of an independent central evaluation of resectability to analyse how it changes during treatment and to define determinants for resection in clinical studies. To address this issue, a post hoc analysis based on a blinded surgical review of imaging was performed on FIRE-3, that will be reported elsewhere.
The relevance of the present analysis is certainly limited by its retrospective nature. Accordingly, imbalances between subgroups cannot be excluded. Further, the currently reported data are relevant only for patients with RAS-WT mCRC.
In conclusion, this analysis of LLD in the FIRE-3 study population revealed a clinically relevant impact of LLD status on OS. The survival benefit of LLD patients was independent of treatment, secondary hepatic resection and further baseline parameters. Consequently, LLD status was identified as an independent prognostic factor in patients with mCRC treated with targeted therapy plus standard chemotherapy.
With regard to the predictive relevance of LLD status in FIRE-3, our data suggest that treatment response and long-term survival favoured first-line FOLFIRI plus cetuximab when compared to FOLFIRI plus bevacizumab irrespectively of LLD status. 
